Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tirzepatide Depot
- Development stage
- Preclinical
- Lead developer
- Mapi Pharma
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
Tirzepatide Depot is a long-acting formulation of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Mapi Pharma for the treatment of diabetes. The drug utilizes Mapi Pharma's proprietary depot technology to provide a sustained-release delivery system, aiming to reduce the frequency of administration compared to existing formulations. It is currently in the early research and development (R&D/IP) phase.
- Other names
- Tirzepatide long-acting injection
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on Tirzepatide Depot.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tirzepatide Depot.